Orm-10103 → 2-(2,4-Difluorophenyl)-6-(5-nitropyridin-2-yloxy)chroman-4-ol
反応式
[N+:1]([C:4]1[CH:5]=[CH:6][C:7](OC2C=C3C(=CC=2)OC(C2C=CC=CC=2)CC3)=[N:8][CH:9]=1)([O-:3])=[O:2].[F:27][C:28]1[CH:33]=[C:32]([F:34])[CH:31]=[CH:30][C:29]=1[CH:35]1[CH2:44][CH:43]([OH:45])[C:42]2[C:37](=[CH:38][CH:39]=[C:40]([OH:46])[CH:41]=2)[O:36]1>>[F:27][C:28]1[CH:33]=[C:32]([F:34])[CH:31]=[CH:30][C:29]=1[CH:35]1[CH2:44][CH:43]([OH:45])[C:42]2[C:37](=[CH:38][CH:39]=[C:40]([O:46][C:7]3[CH:6]=[CH:5][C:4]([N+:1]([O-:3])=[O:2])=[CH:9][N:8]=3)[CH:41]=2)[O:36]1参加物
3
実験手順
2-(2,4-Difluorophenyl)-6-(5-nitropyridin-2-yloxy)chroman-4-ol was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 520 mg of 2-(2,4-difluorophenyl)chroman-4,6-diol (Example 69(b)). The product was recrystallised from a mixture of 2-propanol and diethyl ether. 1H NMR (400 MHz, d6-DMSO) δ: 9.04 (d, 1H, J 2.8 Hz), 8.61 (dd, 1H, J 9.1, 2.8 Hz), 7.66 (m, 1H), 7.32 (m, 1H), 7.26 (d, 1H, J 2.9 Hz), 7.23 (d, 1H, 9.1 Hz), 7.17 (m, 1H), 7.02 (dd, 1H, J 8.9, 2.9 Hz), 6.88 (d, 1H, J 8.9 Hz), 5.70 (bs, 1H), 5.52 (dd, 1H, J 11.9, 1.5 Hz), 5.00 (m, 1H), 2.31 (m, 1H), 2.09 (m, 1H).
後処理
- customThe product was recrystallised from a mixture of 2-propanol and diethyl ether